30 Day Trial

BARE BONES content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Strategic Initiatives

Viscogliosi Bros. Acquiring OP-1 Portfolio -

Ember Therapeutics plans to divest its OP-1 bone morphogenetic protein (BMP-7) portfolio to Viscogliosi Brothers. The transaction is slated to close by 4Q18. BMP-7, marketed as OP-1, has potential use in treatment of osteoarthritis and other non-orthopaedic applications. The OP-1 portfolio includes OP-1 Implant, OP-1 Putty, Opgenra and Osigraft for use in bone applications. At one point OP-1 was viewed as Stryker’s possible competitor to Medtronic’s INFUSE bone graft, but it faced a number of setbacks. (Ember Therapeutics, 8/20/18)